472 top medical experts on Drug-Induced Dyskinesia across 37 countries and 31 U.S. states, including 337 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Drug-Induced Dyskinesia: Abnormal movements, including hyperkinesis; hypokinesia; tremor; and dystonia, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see antipsychotic agents). (Adams et al., Principles of Neurology, 6th ed, p1199)
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): Neurotoxicity Syndromes (2,322), Dyskinesias (4,076), Drug-Related Side Effects and Adverse Reactions (3,185) and Narrower Categories: Tardive Dyskinesia (650).
  4. Clinical Trials ClinicalTrials.gov : at least 15 including 5 Completed, 5 Recruiting
  5. Synonyms: Medication-Induced Dyskinesia


  

        

                    


    These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads, screen scraping or using the data) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

  1. Hauser, Robert A   Neurology   Google Publications
    University of South Florida, Tampa, FL, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial  Review 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 99.7/100
    Disclosed payments in 2021 from 78 biomedical companies, totalling $161,779.99, including $69,657.67 from  Amneal Pharmaceuticals LLC
    Subjects: Dyskinesia, Drug-Induced; Parkinson Disease; Amantadine; Antiparkinson Agents; Levodopa; Delayed-Action Preparations
    Categories: Adverse Effects; Drug Therapy; Therapeutic Use; Administration & Dosage; Diagnosis; Etiology
    ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. (2017)
    Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). (2017)

  2. Goetz, Christopher G   Neurology   ClinicalTrials.gov Google Publications
    Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.
    Physician  Clinical Trial  Review 
    Medical school: Rush Medical College of Rush University (MD, 1975)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 97.2/100
    Disclosed payments from biomedical company (ACADIA Pharmaceuticals Inc) in 2021 for $1,800
    Subjects: Dyskinesia, Drug-Induced; Parkinson Disease; Amantadine; Anticonvulsants; Antiparkinson Agents; Disability Evaluation
    Categories: Adverse Effects; Drug Therapy; Diagnosis; Pharmacology; Therapeutic Use; Antagonists & Inhibitors
    A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. (2016)
    Which dyskinesia scale best detects treatment response? (2013)

  3. Pahwa, Rajesh   Neurology  Google Publications
    University of Kansas Medical Center, Kansas City, KS, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 72.7/100
    Disclosed payments in 2021 from 57 biomedical companies, totalling $57,879.12, including $20,493.6 from  MDD US Operations, LLC
    Subjects: Dyskinesia, Drug-Induced; Amantadine; Levodopa; Antiparkinson Agents; Parkinson Disease; Delayed-Action Preparations
    Categories: Drug Therapy; Adverse Effects; Therapeutic Use; Administration & Dosage; Pharmacology; Etiology
    ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. (2017)
    Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). (2017)

  4. Factor, Stewart A   Neurology   Google Publications
    Jean and Paul Amos Parkinsons Disease and Movement Disorders Program, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: . Top Hospital
    Physician  Clinical Trial  Case Reports 
    Medical school: New York College of Osteo Medicine of New York Institute of Technology (DO, 1982)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 85.6/100
    Disclosed payments in 2021 from 6 biomedical companies, totalling $11,566.04, including $3,725 from  Acorda Therapeutics, Inc
    Subjects: Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease, Secondary; Antiparkinson Agents; Antipsychotic Agents; Dextromethorphan
    Categories: Adverse Effects; Pharmacology; Diagnosis; Drug Therapy; Chemically Induced; Therapeutic Use
    Recent developments in drug-induced movement disorders: a mixed picture. (2019)
    Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease. (2017)

  5. Truong, Daniel D   Neurology   Google Publications
    The Truong Neuroscience Institute, Orange Coast Memorial Medical Center, Fountain Valley, CA, 92708, USA. .
    Physician  Highly Cited  Clinical Trial 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 82/100
    Disclosed payments in 2021 from 355 biomedical companies, totalling $14,078.06, including $7,059.87 from  Amneal Pharmaceuticals LLC
    Subjects: Dyskinesia, Drug-Induced; Amantadine; Antiparkinson Agents; Parkinson Disease; Levodopa; Delayed-Action Preparations
    Categories: Drug Therapy; Administration & Dosage; Adverse Effects; Therapeutic Use; Epidemiology; Etiology
    ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. (2017)
    Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study). (2015)

  6. Jankovic, Joseph   Neurology   Google Publications
    Parkinsons Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston TX, USA. Top Hospital
    Physician  Clinical Trial  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 75.8/100
    Disclosed payments in 2021 from 13 biomedical companies, totalling $83,110.56, including $52,500 from  ACADIA Pharmaceuticals Inc
    Subjects: Dyskinesia, Drug-Induced; Dopamine Antagonists; Levodopa; Akathisia, Drug-Induced; Amantadine; Anti-Dyskinesia Agents
    Categories: Adverse Effects; Drug Therapy; Therapy; Pharmacology; Therapeutic Use; Epidemiology
    Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. (2016)
    Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia. (2016)

  7. Isaacson, Stuart H   Neurology  Google Publications
    Parkinsons Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Disclosed payments in 2021 from 401 biomedical companies, totalling $574,568.2, including $115,879.2 from  ACADIA Pharmaceuticals Inc
    Subjects: Dyskinesia, Drug-Induced; Amantadine; Levodopa; Parkinson Disease; Antiparkinson Agents; Delayed-Action Preparations
    Categories: Drug Therapy; Adverse Effects; Therapeutic Use; Administration & Dosage; Pharmacology; Antagonists & Inhibitors
    ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. (2017)
    Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). (2017)

  8. Chung, Kathryn A   Neurology   ClinicalTrials.gov Google Publications
    Department of Neurology, Oregon Health Sciences University and Veterans Affairs Portland Health Care System, Portland, Oregon, USA.
    Physician  Clinical Trial 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 80.3/100
    Subjects: Dyskinesia, Drug-Induced; Antiparkinson Agents; Amantadine; Anticonvulsants; Levodopa; Postural Balance
    Categories: Adverse Effects; Diagnosis; Therapeutic Use; Drug Therapy; Physiology
    Which dyskinesia scale best detects treatment response? (2013)
    Objective measurement of dyskinesia in Parkinson's disease using a force plate. (2010)

  9. Nelson, Alexandra B   Neurology   Google Publications
    Neuroscience Graduate Program, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: . Top Hospital
    Physician 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 62/100
    Subjects: Dyskinesia, Drug-Induced; Levodopa; Corpus Striatum; Parkinsonian Disorders; Antiparkinson Agents; Dopamine Agents
    Categories: Metabolism; Pathology; Physiopathology; Administration & Dosage; Drug Effects; Toxicity
    A Subpopulation of Striatal Neurons Mediates Levodopa-Induced Dyskinesia. (2018)
    Aberrant Striatal Activity in Parkinsonism and Levodopa-Induced Dyskinesia. (2018)

  10. Friedman, Joseph H   Neurology   Google Publications
    Butler Hospital, Division of Movement Disorders, Warren Alpert Medical School of Brown University, Providence, RI, USA. Electronic address: .
    Physician 
    Medical school: Columbia University College of Physicians and Surgeons (MD, 1978)
    Medicare Accepted
    Subjects: Dyskinesia, Drug-Induced; Akathisia, Drug-Induced; Amantadine; Antidepressive Agents; Antimanic Agents; Antiparkinson Agents
    Categories: Adverse Effects; Chemically Induced; Drug Therapy; Etiology; Therapeutic Use; Diagnosis
    Recent developments in drug-induced movement disorders: a mixed picture. (2019)
    Movement disorders induced by psychiatric drugs that do not block dopamine receptors. (2020)

  11. Caroff, Stanley N   Psychiatry   Google Publications
    Corporal Michael J Crescenz VA Medical Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Top Hospital
    Physician 
    Disclosed payments from biomedical company (Neurocrine Biosciences, Inc.) in 2021 for $2,875
    Subjects: Dyskinesia, Drug-Induced; Antipsychotic Agents; Schizophrenia
    Categories: Adverse Effects; Diagnosis; Drug Therapy; Genetics; Therapy
    Recent developments in drug-induced movement disorders: a mixed picture. (2019)
    Drug-Induced Extrapyramidal Syndromes: Implications for Contemporary Practice. (2016)

  12. Standaert, David G   Neurology   Google Publications
    Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Electronic address: . Top Hospital
    Physician 
    Medical school: Washington University School of Medicine (MD, 1988)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 72.3/100
    Disclosed payments in 2021 from 11 biomedical companies, totalling $12,312.54, including $4,200 from  F. Hoffmann-La Roche AG
    Subjects: Dyskinesia, Drug-Induced; Levodopa; Antiparkinson Agents; Brain; Corpus Striatum; DNA Methylation
    Categories: Metabolism; Physiopathology; Toxicity; Adverse Effects; Drug Effects; Drug Therapy
    Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection? (2019)
    Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia. (2016)

  13. Espay, Alberto J   Neurology   Google Publications
    James J and Joan A Gardner Center for Parkinsons disease and Movement Disorders, University of Cincinnati, Cincinnati, OH, USA.
    Physician  Clinical Trial  Case Reports 
    Medical school: Other (MD, 1994)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Disclosed payments in 2021 from 37 biomedical companies, totalling $50,813.93, including $19,861.39 from  Amneal Pharmaceuticals LLC
    Subjects: Dyskinesia, Drug-Induced; Parkinson Disease; Levodopa; Antiparkinson Agents; Algorithms; Azabicyclo Compounds
    Categories: Pharmacology; Adverse Effects; Drug Therapy; Diagnosis; Complications; Etiology
    Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study. (2021)
    Feasibility of home-based automated Parkinson's disease motor assessment. (2012)

  14. Subramanian, Thyagarajan   Neurology   Google Publications
    Department of Neurology and Neural and Behavioral Sciences, The Pennsylvania State University College of Medicine, Hershey, PA, United States of America. Electronic address: .
    Physician 
    Relevant US NIH Grant Funding: $1,420,296 over the last 5 years
    Medical school: Other (MD, 1985)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 70/100
    Disclosed payments in 2021 from 37 biomedical companies, totalling $46,437.25, including $36,358.73 from  Neurocrine Biosciences, Inc.
    Subjects: Dyskinesia, Drug-Induced; Antiparkinson Agents; Corpus Striatum; Levodopa; MPTP Poisoning; Neural Pathways
    Categories: Physiopathology; Adverse Effects; Physiology; Drug Therapy; Anatomy & Histology; Complications
    A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias. (2010)
    The interhemispheric connections of the striatum: Implications for Parkinson's disease and drug-induced dyskinesias. (2012)

  15. Nutt, John G   Neurology  Google Publications
    Oregon Health and Science University, Portland, Oregon, USA.
    Physician  Clinical Trial  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 80.3/100
    Subjects: Dyskinesia, Drug-Induced; Antiparkinson Agents; Levodopa; Parkinson Disease; Amantadine; Benzothiazoles
    Categories: Adverse Effects; Pharmacology; Drug Therapy; Diagnosis; Etiology; Physiology
    Which dyskinesia scale best detects treatment response? (2013)
    Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease. (2017)

  16. Bishop, Christopher   Family Medicine   Google Publications
    Behavioral Neuroscience Program, Department of Psychology, Binghamton University - State University of New York, Binghamton, NY, USA.
    Physician  Highly Cited  Highly Published 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 84.5/100
    Subjects: Dyskinesia, Drug-Induced; Levodopa; Antiparkinson Agents; Corpus Striatum; Parkinson Disease; Parkinsonian Disorders
    Categories: Metabolism; Drug Therapy; Adverse Effects; Therapeutic Use; Pharmacology; Toxicity
    Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia. (2019)
    Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. (2011)

  17. Lewitt, Peter A   Neurology   Google Publications
    Departments of Neurology, Henry Ford Hospital, Detroit, MI, USA.
    Physician  Clinical Trial 
    Disclosed payments in 2021 from 70 biomedical companies, totalling $90,830.04, including $23,179.62 from  Amneal Pharmaceuticals LLC
    Subjects: Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Antiparasitic Agents; Dopamine; Imidazoles
    Categories: Adverse Effects; Drug Therapy; Administration & Dosage; Metabolism; Pathology
    Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). (2012)
    Relief of parkinsonism and dyskinesia: one and the same dopaminergic mechanism? (2010)

  18. Sullivan, Patrick F   Psychiatry   Google Publications
    Department of Genetics, University of North Carolina, Chapel Hill, NC fernando_pardo-manuel@med.unc.edu patrick_sullivan@med.unc.edu.
    Physician 
    Subjects: Dyskinesia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Genome-Wide Association Study; Schizophrenia
    Categories: Genetics; Adverse Effects; Drug Therapy
    Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice. (2012)
    Antipsychotic Behavioral Phenotypes in the Mouse Collaborative Cross Recombinant Inbred Inter-Crosses (RIX). (2020)

  19. Sherman, Scott J   Neurology   Google Publications
    University of Arizona, College of Medicine, Department of Neurology, 1501 N. Campbell Ave., Tucson, AZ, USA. Electronic address: . Top Hospital
    Physician  Highly Published 
    Medical school: University of Washington School of Medicine (MD, 1985)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 74/100
    Disclosed payments in 2021 from 5 biomedical companies, totalling $6,392.5, including $6,330 from  GE HEALTHCARE
    Subjects: Dyskinesia, Drug-Induced; Levodopa; Ketamine; Antiparkinson Agents; Excitatory Amino Acid Antagonists; Glycopeptides
    Categories: Therapeutic Use; Adverse Effects; Drug Therapy; Antagonists & Inhibitors; Prevention & Control; Administration & Dosage
    Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia. (2020)
    Highly-selective µ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model. (2020)

  20. Nicholas, Anthony P   Neurology  Google Publications
    Department of Neurology, University of Alabama and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama, USA.
    Physician  Clinical Trial 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 72.3/100
    Disclosed payments from biomedical company (F. Hoffmann-La Roche AG) in 2021 for $374.16
    Subjects: Dyskinesia, Drug-Induced; Amantadine; Anticonvulsants; Antiparkinson Agents; Imidazoles; Indans
    Categories: Adverse Effects; Drug Therapy; Administration & Dosage; Therapeutic Use; Diagnosis
    Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). (2012)
    Which dyskinesia scale best detects treatment response? (2013)

Note:
  1. Only the top 20 experts are shown. You may filter your results or use the geolocation tabs. Contact us to purchase the entire list.
These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads or screen scraping) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

);